Central Precocious Puberty in Males, GnRH Analog Treated or Untreated, Did Not Impact Fertility and Health in Midadulthood.

Abstract

The long-term health consequences of idiopathic central precocious puberty (ICPP) in males, whether treated or untreated, are not well established. To evaluate general health and metabolic outcomes in adult men with a history of ICPP. Retrospective cohort study with age, birth year, and socioeconomic status-matched controls. One hundred eighteen men aged 29 to 48 years with a history of ICPP (68 GnRH analog treated, 50 untreated) and 351 matched controls (204 matched to the treated group and 147 to the untreated group). Data were extracted from the Clalit Health Services database and included demographics, medical history, medication records, anthropometric data, and laboratory results. Prevalence of reproductive issues, metabolic conditions (obesity, hypertension, hyperlipidemia, diabetes), osteoporosis, malignancy, and psychopathology. The median age was 40 years in the treated and 44 years in the untreated ICPP group (P < .001). No significant differences were observed between treated and untreated groups in the prevalence of reproductive issues (11.8% vs 18.4%, P = .317), metabolic disorders (35.3% vs 34.7%, P = .946), cardiovascular conditions (16.2% vs 14.3%, P = .780), bone health problems (4.4% vs 4.1%, P = .931), psychopathology (19.1% vs 16.3%, P = .698), or malignancies (1.5% vs 8.2%, P = .160). Reproductive and health outcomes were also comparable between ICPP patients and their respective control groups, regardless of treatment history. A history of ICPP in males, whether treated or untreated, does not appear to be associated with adverse long-term outcomes in reproductive, metabolic, emotional, or oncological health. Overall, adult men with prior ICPP exhibit similar health profiles to those of the general population.